Amedeo Smart

Free Medical Literature Service

 

Amedeo

Prostate Cancer
  Free Subscription

Articles published in
Prostate
    December 2024
  1. OLDAN JD, Rowe SP, Schroeder JA
    Evaluation of online teaching modules for PSMA PET interpretation.
    Prostate. 2024;84:1419-1426.
    >> Share

    November 2024
  2. MIYAHIRA AK, Sharifi M, Chesner LN, El-Kenawi A, et al
    Personalized Medicine: Leave no Patient Behind; Report From the 2024 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Nov 27. doi: 10.1002/pros.24826.
    >> Share

  3. HE E, Li Y, Zhao R, Kong Q, et al
    IL7 as a Risk Factor for Prostate Cancer: Implications for T Cell Apoptosis and Infiltration in the Tumor Microenvironment.
    Prostate. 2024 Nov 26. doi: 10.1002/pros.24830.
    >> Share

  4. GLADIS PUSHPARATHI VP, Justin Xavier D, Chitra P, Kannan G, et al
    Prostate Cancer Classification and Interpretation With Multiparametric Magnetic Resonance Imaging and Gleason Grade Score Using DarkNet53 Model.
    Prostate. 2024 Nov 25:e24827. doi: 10.1002/pros.24827.
    >> Share

  5. NAGASAKA H, Sato S, Suzuki A, Terao H, et al
    Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer.
    Prostate. 2024 Nov 20. doi: 10.1002/pros.24825.
    >> Share


  6. RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERalpha.
    Prostate. 2024 Nov 17. doi: 10.1002/pros.24822.
    >> Share

  7. JUNIOR EP, Gomes EFDA, de Lima MFR, Raimundo JVS, et al
    Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for Progression and Prognostic Assessment.
    Prostate. 2024 Nov 13. doi: 10.1002/pros.24824.
    >> Share

  8. BIALAS P, Kobayashi T, Hellsten R, Krzyzanowska A, et al
    pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of Androgen Deprivation Therapy.
    Prostate. 2024 Nov 11. doi: 10.1002/pros.24820.
    >> Share

  9. TAKAHASHI T, Nakashima M, Maruno K, Hazama T, et al
    Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System.
    Prostate. 2024 Nov 10. doi: 10.1002/pros.24821.
    >> Share

  10. TAO H, Wu F, Li R, Du X, et al
    Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24817.
    >> Share

  11. ZHAO X, Sakamoto S, Ishikawa H, Yamada Y, et al
    Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam Radiation Therapy.
    Prostate. 2024 Nov 3. doi: 10.1002/pros.24818.
    >> Share

    October 2024
  12. WEI X, Zhao J, Nie L, Shi Y, et al
    Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients.
    Prostate. 2024 Oct 28. doi: 10.1002/pros.24809.
    >> Share

  13. FINATI M, Morrison C, Stephens A, Chiarelli G, et al
    Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.
    Prostate. 2024 Oct 28:e24803. doi: 10.1002/pros.24803.
    >> Share

  14. WHYNE EZ, Jeon-Slaughter H, Kelly K, Dowell JE, et al
    Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective Study.
    Prostate. 2024 Oct 28. doi: 10.1002/pros.24811.
    >> Share

  15. DI BELLO F, Jannello LMI, Baudo A, de Angelis M, et al
    Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus Population-Based Controls According to Treatment Type.
    Prostate. 2024 Oct 24:e24816. doi: 10.1002/pros.24816.
    >> Share

  16. ERTL IE, Lemberger U, Rajwa P, Petrov P, et al
    Low SMARCD3 expression is associated with poor prognosis in patients with prostate cancer.
    Prostate. 2024 Oct 23. doi: 10.1002/pros.24815.
    >> Share

  17. SHUKLA S, Osumi T, Al-Toubat M, Serrano S, et al
    Protein kinase D1 mitigation against etoposide induced DNA damage in prostate cancer is associated with increased alpha-Catenin.
    Prostate. 2024 Oct 20. doi: 10.1002/pros.24812.
    >> Share

  18. YANAGISAWA T, Fukuokaya W, Hatakeyama S, Narita S, et al
    Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
    Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813.
    >> Share

  19. SEMWAL H, Ladbury C, Sabbagh A, Mohamad O, et al
    Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.
    Prostate. 2024 Oct 13. doi: 10.1002/pros.24793.
    >> Share

  20. FALKENBACH F, Schmalhofer ML, Tian Z, Mazzucato G, et al
    Size and SUV(max) define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.
    Prostate. 2024 Oct 9. doi: 10.1002/pros.24806.
    >> Share

  21. TSAI K, Xu P, Guo J, Dean N, et al
    Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium laser enucleation of prostate outcomes?
    Prostate. 2024;84:1344-1351.
    >> Share

    September 2024
  22. DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al
    Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24799.
    >> Share

  23. NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al
    Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
    Prostate. 2024 Sep 30. doi: 10.1002/pros.24802.
    >> Share

  24. YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al
    The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 ((177)Lu)-PSMA-617.
    Prostate. 2024 Sep 29. doi: 10.1002/pros.24804.
    >> Share

  25. MURTA CB, Junior JP, de Souza Filho PHF, de Godoy Junior PC, et al
    Prostate cancer focal therapy: surgeon experience influences oncological results.
    Prostate. 2024 Sep 26. doi: 10.1002/pros.24800.
    >> Share

  26. TRAN EU, Ovruchesky E, Yamamoto K, Marley S, et al
    Bipolar androgen therapy for treatment of metastatic castration-resistant prostate cancer: A case series.
    Prostate. 2024 Sep 22. doi: 10.1002/pros.24798.
    >> Share

  27. TANAKA N, Izumi K, Nakai Y, Shima T, et al
    Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: A subanalysis from the ENABLE study for PCa.
    Prostate. 2024 Sep 20. doi: 10.1002/pros.24796.
    >> Share

  28. WONG CH, Ko IC, Leung DK, Siu B, et al
    Deep PSA response and extended time-to-nadir as robust predictors of survival in Asian patients with de novo metastatic hormone-sensitive prostate cancer receiving upfront intensified treatment.
    Prostate. 2024 Sep 19. doi: 10.1002/pros.24797.
    >> Share

  29. DE JESUS GNC, Pereira V, Karak P, Shearier E, et al
    A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
    Prostate. 2024 Sep 18. doi: 10.1002/pros.24795.
    >> Share

  30. UEKI H, Jimbo N, Terakawa T, Hara T, et al
    Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24791.
    >> Share

  31. KATO T, Sugihara E, Hata Y, Kawakami K, et al
    Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among patients with prostate cancer.
    Prostate. 2024 Sep 15. doi: 10.1002/pros.24792.
    >> Share

  32. LIU X, Zhu J, Shi MQ, Pan YS, et al
    Predicting clinically significant prostate cancer in elderly patients: A nomogram approach with shear wave elastography.
    Prostate. 2024 Sep 12. doi: 10.1002/pros.24789.
    >> Share

  33. BOIARSKY D, Tewari AK, Gulhan DC, Bakouny Z, et al
    A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.
    Prostate. 2024 Sep 9. doi: 10.1002/pros.24788.
    >> Share

  34. MATRONE F, Del Ben F, Montico M, Muraro E, et al
    Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive prostate cancer patients undergoing stereotactic body radiation therapy.
    Prostate. 2024 Sep 6. doi: 10.1002/pros.24787.
    >> Share

  35. HIMMELSBACH R, Hacklander A, Weishaar M, Morlock J, et al
    Retrospective analysis of the learning curve in perineal robot-assisted prostate biopsy.
    Prostate. 2024;84:1165-1172.
    >> Share

  36. OZKAYA M, Simsekoglu MF, Kalender G, Sahin KC, et al
    Clinical and histopathological parameters in transrectal ultrasound-guided biopsies associated with tumor upgrading after radical prostatectomy: A comparative analysis of risk groups.
    Prostate. 2024;84:1146-1156.
    >> Share

  37. BARRIERE H, Kaulanjan K, Stempfer G, Mollard P, et al
    Overall and metastasis-free survival of Afro-Caribbean patients with biochemical recurrence after radical prostatectomy.
    Prostate. 2024;84:1112-1118.
    >> Share

  38. WEI Y, Wang H, Xie D, Lu J, et al
    Analysis of three primary prostatic sarcoma cases and literature review.
    Prostate. 2024;84:1218-1223.
    >> Share

  39. CHEN VS, James C, Khemmani M, Desai S, et al
    A prospective evaluation of the prostate microbiome in malignant and benign tissue using transperineal biopsy.
    Prostate. 2024;84:1251-1261.
    >> Share

  40. ADAMS ES, Deivasigamani S, Kotamarti S, Wolf S, et al
    Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes.
    Prostate. 2024;84:1224-1233.
    >> Share

  41. MADENDERE S, Kilic M, Zoroglu H, Sarikaya AF, et al
    Natural history of histologically benign PIRADS 4-5 lesions in multiparametric MRI: Real-life experience in an academic center.
    Prostate. 2024;84:1262-1267.
    >> Share

  42. FALKENBACH F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, et al
    Bimodal imaging: Detection rate of clinically significant prostate cancer is higher in MRI lesions visible to transrectal ultrasound.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24785.
    >> Share

  43. LU S, Lamba M, Wang J, Dong Z, et al
    Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.
    Prostate. 2024 Sep 1. doi: 10.1002/pros.24786.
    >> Share

    August 2024
  44. TANEGASHIMA T, Shiota M, Eto M
    Reply to Letter to the Editor on "Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients".
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24784.
    >> Share

  45. WANG J, Lao Y, Guan X, Li Z, et al
    Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24671.
    >> Share

  46. SAHEB SHARIF-ASKARI F, Al-Shahrabi R, Al Shareef Z
    Response to the letter to the editor: Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2024 Aug 21. doi: 10.1002/pros.24779.
    >> Share

  47. SWAMI U, Xie B, Young C, Ramaswamy K, et al
    Real-world prevalence of adverse events with first-line systemic therapies among patients with metastatic castration-sensitive prostate cancer.
    Prostate. 2024 Aug 20. doi: 10.1002/pros.24777.
    >> Share

  48. LI EV, Lee MS, Guo J, Dean N, et al
    Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate.
    Prostate. 2024 Aug 18. doi: 10.1002/pros.24781.
    >> Share

  49. HSIEH CL, Do AD, Hsueh CY, Raboshakga MO, et al
    L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.
    Prostate. 2024 Aug 18. doi: 10.1002/pros.24782.
    >> Share

  50. LIU T, Joshu CE, Lu J, Prizment A, et al
    Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study.
    Prostate. 2024 Aug 15. doi: 10.1002/pros.24774.
    >> Share

  51. WANG H, He K, Liu Y, Yang L, et al
    Expression and immune infiltration studies of IL-33-ST2-NF-kappaB signaling pathway in prostate cancer.
    Prostate. 2024 Aug 7. doi: 10.1002/pros.24778.
    >> Share

  52. WAKAMORI C, De Velasco MA, Sakai K, Kura Y, et al
    A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk.
    Prostate. 2024 Aug 7. doi: 10.1002/pros.24776.
    >> Share

  53. ONAL C, Guler OC, Torun N, Elmali A, et al
    Impact of definitive radiotherapy on metabolic response measured with (68)Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.
    Prostate. 2024 Aug 6. doi: 10.1002/pros.24775.
    >> Share

  54. GREENLAND NY, Cooperberg MR, Carroll PR, Cowan JE, et al
    Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification.
    Prostate. 2024;84:1076-1085.
    >> Share

  55. PETERS DE, Brownlee M, Layne-Colon D, Slusher BS, et al
    Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus).
    Prostate. 2024;84:1086-1088.
    >> Share

    July 2024
  56. SCHMIT S, Malshy K, Ochsner A, Golijanin B, et al
    Lower urinary tract symptoms in elderly men: Considerations for prostate cancer testing.
    Prostate. 2024 Jul 25. doi: 10.1002/pros.24772.
    >> Share

  57. FRIEDRICH NA, Gu L, Waller J, De Hoedt AM, et al
    Real-world evidence of (18)F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System.
    Prostate. 2024 Jul 19. doi: 10.1002/pros.24770.
    >> Share

  58. MIYAHIRA AK, Soule HR
    The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24768.
    >> Share

  59. SUTERA P, Kim J, Kumar R, Deek RA, et al
    PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.
    Prostate. 2024 Jul 17. doi: 10.1002/pros.24765.
    >> Share

  60. TANEGASHIMA T, Shiota M, Tsukahara S, Mutaguch J, et al
    Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients.
    Prostate. 2024 Jul 10. doi: 10.1002/pros.24769.
    >> Share

  61. WENZEL M, Wagner N, Hoeh B, Siech C, et al
    Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.
    Prostate. 2024 Jul 10. doi: 10.1002/pros.24767.
    >> Share

  62. JASMINE S, Mandl A, Krueger TEG, Dalrymple SL, et al
    Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.
    Prostate. 2024;84:909-921.
    >> Share

    June 2024
  63. KAYAR R, Tokuc E, Ozsoy E, Demir S, et al
    The predictive impact of hematological inflammatory markers in detecting prostate cancer in patients with PI-RADS 3 lesions on multiparametric magnetic resonance imaging.
    Prostate. 2024 Jun 26. doi: 10.1002/pros.24762.
    >> Share

  64. MASSANOVA M, Barone B, Caputo VF, Napolitano L, et al
    The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study.
    Prostate. 2024 Jun 25. doi: 10.1002/pros.24761.
    >> Share

  65. PRAKASH P, Verma S, Gupta S
    Influence of microbiome in intraprostatic inflammation and prostate cancer.
    Prostate. 2024 Jun 20. doi: 10.1002/pros.24756.
    >> Share

  66. MALSHY K, Ochsner A, Homer A, Allu S, et al
    Consistent predictive ability of prostate-specific antigen density prediction model for clinically significant prostate cancer across age strata.
    Prostate. 2024 Jun 20. doi: 10.1002/pros.24757.
    >> Share

  67. CORDOBA SANCHEZ J, Monge-Escartin I, Gil J, Carrera C, et al
    Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.
    Prostate. 2024 Jun 18. doi: 10.1002/pros.24755.
    >> Share

  68. ABRAMOVIC I, Pezelj I, Dumbovic L, Skara Abramovic L, et al
    LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
    Prostate. 2024 Jun 2. doi: 10.1002/pros.24749.
    >> Share

  69. DONG Q, Wang C, Shen D, Ma Y, et al
    Combination of prostate volume and apparent diffusion coefficient can stratify patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
    Prostate. 2024;84:780-787.
    >> Share

  70. BUTTNER T, Gartner F, Essler M, Weiten R, et al
    Key learnings from concordant systematic biopsies in prostate-specific membrane antigen positron emission tomography/computed tomography-guided prostate biopsies: Enhancing targeting accuracy.
    Prostate. 2024;84:772-779.
    >> Share

  71. FLETCHER SA, Mamawala MM, Holler AE, Bhanji Y, et al
    Cumulative cancer locations on prostate biopsy and active surveillance outcomes in the MRI era.
    Prostate. 2024;84:723-730.
    >> Share

  72. BENNETT R 4TH, Li EV, Ho AY, Aguiar JA, et al
    Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system.
    Prostate. 2024;84:717-722.
    >> Share

  73. CHECCUCCI E, De Cillis S, Alladio E, Piramide F, et al
    Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy.
    Prostate. 2024;84:832-841.
    >> Share

    May 2024
  74. WENZEL M, Hoeh B, Hurst F, Koll F, et al
    Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
    Prostate. 2024 May 29. doi: 10.1002/pros.24754.
    >> Share

  75. TOUMA N, Larose M, Ouellet J, Bedard-Tremblay D, et al
    External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer patients.
    Prostate. 2024 May 27. doi: 10.1002/pros.24742.
    >> Share

  76. TIRUYE T, Roder D, FitzGerald LM, O'Callaghan M, et al
    Impact of comorbidities on prostate cancer-specific mortality: A population-based cohort study.
    Prostate. 2024 May 26. doi: 10.1002/pros.24750.
    >> Share

  77. FERRO M, Crocetto F, La Civita E, Fiorenza M, et al
    Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index, and prostate health index density as clues to reveal postoperative clinically significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
    Prostate. 2024 May 26. doi: 10.1002/pros.24752.
    >> Share

  78. ABEDALI Z, Woloshuk A, Cary C, Boris RS, et al
    Does larger prostate size provide protection for cancer specific outcomes in localized prostate cancer.
    Prostate. 2024 May 16. doi: 10.1002/pros.24743.
    >> Share

  79. BUTTNER T, Klumper N, Weiten R, Lossin P, et al
    Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2024 May 15. doi: 10.1002/pros.24747.
    >> Share

  80. NAKAI Y, Tanaka N, Asakawa I, Ohnishi K, et al
    Efficacy of a hydrogel spacer for improving quality of life in patients with prostate cancer undergoing low-dose-rate brachytherapy alone or in combination with intensity-modulated radiotherapy: An observational study using propensity score matching.
    Prostate. 2024 May 12. doi: 10.1002/pros.24744.
    >> Share

  81. MACKAY S, Oduor IO, Burch TC, Main BP, et al
    Increased alpha2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in post-DRE urine is associated with high grade group prostate cancer.
    Prostate. 2024 May 12. doi: 10.1002/pros.24724.
    >> Share

  82. ASHIDA S, Kawada C, Tanaka H, Kurabayashi A, et al
    Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a possible pathogen of prostate cancer.
    Prostate. 2024 May 9. doi: 10.1002/pros.24723.
    >> Share

  83. YIN J, Daryanani A, Lu F, Ku AT, et al
    Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
    Prostate. 2024 May 6. doi: 10.1002/pros.24718.
    >> Share

  84. HEETMAN JG, Paulino Pereira LJ, Kelder JC, Soeterik TFW, et al
    The additional value of (68)Ga-PSMA PET/CT SUVmax in predicting ISUP GG >/= 2 and ISUP GG >/= 3 prostate cancer in biopsy.
    Prostate. 2024 May 5. doi: 10.1002/pros.24716.
    >> Share

  85. QAZI SU, Altaf Z, Zafar M, Tariq MA, et al
    Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
    Prostate. 2024;84:525-538.
    >> Share

  86. ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al
    Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.
    Prostate. 2024;84:513-524.
    >> Share

  87. BERG FM, Correia ETO, Abenojar EC, Basilion JP, et al
    Multispecies comparative prostate anatomy by imaging: Implications for experimental models of prostatic disease.
    Prostate. 2024;84:682-693.
    >> Share

  88. SIMANEK V, Vrzakova R, Vitak R, Jirasko M, et al
    Preanalytical stability of molecular forms of prostate-specific antigen in serum samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
    Prostate. 2024;84:656-665.
    >> Share

  89. KOSTECKA LG, Mendez S, Li M, Khare P, et al
    Cancer cells employ lipid droplets to survive toxic stress.
    Prostate. 2024;84:644-655.
    >> Share

    April 2024
  90. KARSH L, Du S, He J, Waters D, et al
    Differences in real-world outcomes by risk classification for localized prostate cancer patients after radiation therapy.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24720.
    >> Share

  91. MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al
    Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting.
    Prostate. 2024 Apr 29. doi: 10.1002/pros.24721.
    >> Share

  92. NGUYEN AM, Carter GC, Wilson LM, Canfield S, et al
    Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score(R) (GPS(TM)) assay.
    Prostate. 2024 Apr 26. doi: 10.1002/pros.24709.
    >> Share

  93. CHARLTON PV, O'Reilly D, Philippou Y, Rao SR, et al
    Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.
    Prostate. 2024 Apr 23. doi: 10.1002/pros.24715.
    >> Share

  94. KAREGAR-NIAVOL R, Ghaffari F, Saravi A, Fotokian Z, et al
    Translation and validation of a lifestyle questionnaire related to prostate cancer.
    Prostate. 2024 Apr 21. doi: 10.1002/pros.24713.
    >> Share

  95. MARSHALL CH, Gondek LP, Daniels V, Lu C, et al
    Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
    Prostate. 2024 Apr 20. doi: 10.1002/pros.24712.
    >> Share

  96. JIA T, Liu C, Guo P, Xu Y, et al
    FOXA1 regulates ribosomal RNA transcription in prostate cancer.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24714.
    >> Share

  97. ZHAO F, Zhao J, Wei X, Shi Y, et al
    Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24710.
    >> Share

  98. GRINDEDAL EM, Zucknick M, Stormorken A, Ronne E, et al
    Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome.
    Prostate. 2024 Apr 17. doi: 10.1002/pros.24711.
    >> Share

  99. CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al
    An orthotopic prostate cancer model for new treatment development using syngeneic or patient-derived tumors.
    Prostate. 2024 Apr 12. doi: 10.1002/pros.24701.
    >> Share

  100. BROWN LK, Kanagasabai T, Li G, Celada SI, et al
    Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.
    Prostate. 2024 Apr 11. doi: 10.1002/pros.24706.
    >> Share

  101. MARTELIN N, De Witt B, Chen B, Eschwege P, et al
    Development and validation of an imageless machine-learning algorithm for the initial screening of prostate cancer.
    Prostate. 2024 Apr 4. doi: 10.1002/pros.24703.
    >> Share

  102. MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al
    Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole blood.
    Prostate. 2024 Apr 3. doi: 10.1002/pros.24704.
    >> Share

  103. ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al
    Distribution of neurovascular structures within the prostate gland and their relationship to complications after radical prostatectomy.
    Prostate. 2024;84:491-501.
    >> Share

  104. GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al
    Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24696.
    >> Share

  105. KIM J, Park S, Kim S, Ryu S, et al
    Enhancing the anticancer effect of androgen deprivation therapy by monocarboxylate transporter 1 inhibitor in prostate cancer cells.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24700.
    >> Share

  106. KU HC, Cheng E, Cheng CF
    A body shape index (ABSI) but not body mass index (BMI) is associated with prostate cancer-specific mortality: Evidence from the US NHANES database.
    Prostate. 2024 Apr 1. doi: 10.1002/pros.24698.
    >> Share

    March 2024
  107. SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al
    Quantification and molecular correlates of tertiary lymphoid structures in primary prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24684.
    >> Share

  108. MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al
    Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
    Prostate. 2024 Mar 27. doi: 10.1002/pros.24691.
    >> Share

  109. DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al
    CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24690.
    >> Share

  110. ONAL C, Guler OC, Erbay G, Elmali A, et al
    The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on the use of short-term androgen deprivation therapy in patients with intermediate risk prostate cancer.
    Prostate. 2024 Mar 25. doi: 10.1002/pros.24693.
    >> Share

  111. DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al
    Other-cause mortality in incidental prostate cancer.
    Prostate. 2024 Mar 20. doi: 10.1002/pros.24689.
    >> Share

  112. HEERS H, Chwilka O, Huber J, Vogelmeier C, et al
    VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
    Prostate. 2024 Mar 18. doi: 10.1002/pros.24692.
    >> Share

  113. GU J, Chery L, Gonzalez GMN, Huff C, et al
    A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening.
    Prostate. 2024 Mar 13. doi: 10.1002/pros.24686.
    >> Share

  114. BRENNEN WN, Le Magnen C, Karkampouna S, Anselmino N, et al
    Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
    Prostate. 2024 Mar 7. doi: 10.1002/pros.24682.
    >> Share

  115. HUANG H, Liu Z, Ma Y, Shao Y, et al
    Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in patients with PSA 4-20 ng/mL.
    Prostate. 2024;84:376-388.
    >> Share

    February 2024
  116. KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al
    Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
    Prostate. 2024 Feb 27. doi: 10.1002/pros.24679.
    >> Share

  117. YE PC, Leu WJ, Yeh TY, Hsu YT, et al
    A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
    Prostate. 2024 Feb 20. doi: 10.1002/pros.24678.
    >> Share

  118. LUO LS, Huang J, Luan HH, Mubarik S, et al
    Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990-2019: A comparable study of key nations with emerging economies.
    Prostate. 2024 Feb 8. doi: 10.1002/pros.24673.
    >> Share

  119. ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al
    Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24674.
    >> Share

  120. HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al
    Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24672.
    >> Share

    January 2024
  121. PANACH-NAVARRETE J, Gonzalez-Marrachelli V, Morales-Tatay JM, Garcia-Morata F, et al
    Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
    Prostate. 2024 Jan 11. doi: 10.1002/pros.24670.
    >> Share

  122. WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al
    Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways.
    Prostate. 2024 Jan 8. doi: 10.1002/pros.24662.
    >> Share

  123. DE KOUCHKOVSKY I, Chan E, Schloss C, Poehlein C, et al
    Diagnosis and management of neuroendocrine prostate cancer.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24664.
    >> Share

  124. ZHANG C, Tu X, Dai J, Zhang Z, et al
    Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its impact on prostate cancer detection: Real-world insights from a high-volume center in southwest China.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24669.
    >> Share

  125. OZAWA Y, Nohara S, Nakamura K, Hattori S, et al
    Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
    Prostate. 2024 Jan 3. doi: 10.1002/pros.24668.
    >> Share

    December 2023
  126. MACKAY S, Oduor IO, Burch TC, Troyer DA, et al
    Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma.
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24666.
    >> Share

  127. PELLEGRINO F, Stabile A, Sorce G, Mazzone E, et al
    Variability of mpMRI diagnostic performance according to the upfront individual patient risk of having clinically significant prostate cancer.
    Prostate. 2023 Dec 27. doi: 10.1002/pros.24665.
    >> Share

  128. XIE H, Chen J, Ma Z, Gao Y, et al
    PrLZ regulates EMT and invasion in prostate cancer via the TGF-beta1/p-smad2/miR-200 family/ZEB1 axis.
    Prostate. 2023 Dec 25. doi: 10.1002/pros.24647.
    >> Share

  129. CANCEL M, Crottes D, Bellanger D, Bruyere F, et al
    Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
    Prostate. 2023 Dec 19. doi: 10.1002/pros.24655.
    >> Share

  130. D'AGOSTINO GR, Badalamenti M, Stefanini S, Baldaccini D, et al
    Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
    Prostate. 2023 Dec 19. doi: 10.1002/pros.24657.
    >> Share

  131. LUKEZ A, Handorf E, Mendenhall NP, Henderson RH, et al
    A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.
    Prostate. 2023 Dec 18. doi: 10.1002/pros.24660.
    >> Share

  132. MOON D, Hauck JS, Jiang X, Quang H, et al
    Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor growth of castration-resistant prostate cancer.
    Prostate. 2023 Dec 12. doi: 10.1002/pros.24654.
    >> Share

  133. ZENG J, Zhang Y, Xu R, Chen H, et al
    Nanomechanical-based classification of prostate tumor using atomic force microscopy.
    Prostate. 2023;83:1591-1601.
    >> Share

  134. BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al
    Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
    Prostate. 2023;83:1519-1528.
    >> Share

  135. RAVI P, Kwak L, Devlies W, Xie W, et al
    Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
    Prostate. 2023 Dec 1. doi: 10.1002/pros.24653.
    >> Share

    November 2023
  136. AL SHAREEF Z, Al-Shahrabi R, Saheb Sharif-Askari F, AlDhmanie A, et al
    Incidence and risk factors of prostate cancer among the Northern and Eastern parts of the United Arab Emirates population.
    Prostate. 2023 Nov 15:e24637. doi: 10.1002/pros.24637.
    >> Share

  137. PALLER CJ, Barata PC, Lorentz J, Appleman LJ, et al
    PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
    Prostate. 2023 Nov 14. doi: 10.1002/pros.24650.
    >> Share

  138. MULLEN SA, Das D, Ziamiavaghi N, High R, et al
    Association of plasma NRP2 and VEGF-C levels with prostate cancer disease severity.
    Prostate. 2023 Nov 9. doi: 10.1002/pros.24648.
    >> Share

  139. LI J, Wang K, Li S, Wu P, et al
    Clinical study of multifactorial diagnosis in prostate biopsy.
    Prostate. 2023;83:1494-1503.
    >> Share

  140. MIYAHIRA AK, Soule HR
    The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640.
    >> Share

  141. GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al
    Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2023 Nov 1. doi: 10.1002/pros.24644.
    >> Share

    October 2023
  142. ALSAIDAN OA, Onobun E, Ye C, Lou L, et al
    Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24645.
    >> Share

  143. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    >> Share

  144. FU W, Xu L, Chen Y, Zhang Z, et al
    Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
    Prostate. 2023 Oct 30. doi: 10.1002/pros.24642.
    >> Share

  145. MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al
    Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24643.
    >> Share

  146. ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al
    Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.
    Prostate. 2023 Oct 27. doi: 10.1002/pros.24631.
    >> Share

  147. HU HP, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, et al
    Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
    Prostate. 2023 Oct 25. doi: 10.1002/pros.24638.
    >> Share

  148. MITCHELL AP, Persaud S, Palyca P, Salner A, et al
    Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancer.
    Prostate. 2023 Oct 16. doi: 10.1002/pros.24636.
    >> Share

  149. SIEGELMANN-DANIELI N, Neiman V, Bareket-Samish A, Berger R, et al
    Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Prostate. 2023 Oct 16. doi: 10.1002/pros.24622.
    >> Share

  150. MENEZES RDS, Dornas MC, Campos CFF, Rodeiro DB, et al
    Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
    Prostate. 2023 Oct 15. doi: 10.1002/pros.24635.
    >> Share

  151. PEDRAZA AM, Gupta R, Musheyev D, Pino T, et al
    Microultrasound in the detection of the index lesion in prostate cancer.
    Prostate. 2023 Oct 12. doi: 10.1002/pros.24628.
    >> Share

  152. WANG L, Lyu C, Stadlbauer B, Buchner A, et al
    Berbamine targets cancer stem cells and reverses cabazitaxel resistance via inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
    Prostate. 2023 Oct 12. doi: 10.1002/pros.24632.
    >> Share

  153. HOANG T, Sutera P, Nguyen T, Chang J, et al
    TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
    Prostate. 2023 Oct 9. doi: 10.1002/pros.24629.
    >> Share

  154. LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
    Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
    Prostate. 2023 Oct 5. doi: 10.1002/pros.24630.
    >> Share

  155. HEETMAN JG, Hermsen R, Exterkate L, Kusters-Vandevelde HVN, et al
    Immunohistochemical and histopathological validation of (18) F-PSMA-1007 PET/CT for intraprostatic cancerous lesions.
    Prostate. 2023;83:1332-1341.
    >> Share

    September 2023
  156. ARAFA MA, Farhat KH, Khan FK, Rabah DM, et al
    Development and internal validation of a nomogram predicting significant prostate cancer: Is it clinically applicable in low prevalent prostate cancer countries? A multicenter study.
    Prostate. 2023 Sep 27. doi: 10.1002/pros.24625.
    >> Share

  157. RAJWA P, Heidenreich J, Drzezga A, Schmidt M, et al
    The diagnostic accuracy of (68) Ga-PSMA-PET/CT in primary staging of patients with high-risk nonmetastatic prostate cancer treated with radical prostatectomy: A single-center cohort analysis.
    Prostate. 2023 Sep 26. doi: 10.1002/pros.24627.
    >> Share

  158. ZOU P, Chen Z, He Q, Zhuo Y, et al
    Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells through the ERK/DNMT1/ACSL4 axis.
    Prostate. 2023 Sep 26. doi: 10.1002/pros.24626.
    >> Share

  159. KOELKER M, Labban M, Frego N, Ye J, et al
    Racial differences in patient-reported outcomes among men treated with radical prostatectomy for prostate cancer.
    Prostate. 2023 Sep 14. doi: 10.1002/pros.24624.
    >> Share

  160. ULERI A, Baboudjian M, Tedde A, Rajwa P, et al
    The association between beta-blockers use and prostate cancer mortality: A mini systematic review and meta-analysis.
    Prostate. 2023 Sep 14. doi: 10.1002/pros.24623.
    >> Share

  161. YAMADA Y, Sakamoto S, Sato K, Saito S, et al
    Clinical utility of the prognostic nutritional index in patients with metastatic hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
    Prostate. 2023 Sep 10. doi: 10.1002/pros.24619.
    >> Share

  162. ESEN B, Seymen H, Gurses B, Armutlu A, et al
    The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24621.
    >> Share

  163. FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al
    Prognostic significance of serum testosterone level in patients with castration-resistant prostate cancer treated with cabazitaxel.
    Prostate. 2023 Sep 3. doi: 10.1002/pros.24620.
    >> Share

  164. WANG M, Lange A, Perlman D, Qi J, et al
    Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance.
    Prostate. 2023;83:1141-1149.
    >> Share

  165. DIKOV D, Koleva M, Mollova A, Fakirova A, et al
    Strong PD-L1 expression in granulomatous prostatitis.
    Prostate. 2023;83:1285-1289.
    >> Share

  166. HAEUSER L, Tully KH, Reicherz A, Berg S, et al
    Functional outcome after radical prostatectomy in 1313 patients: A single-center study.
    Prostate. 2023;83:1290-1297.
    >> Share

  167. MCMANUS JM, Chung YM, Sharifi N
    3betaHSD activity saturates at physiological substrate concentrations in intact cells.
    Prostate. 2023;83:1306-1309.
    >> Share

  168. YUSIM I, Mazor E, Frumkin E, Jabareen M, et al
    Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Prostate. 2023;83:1255-1262.
    >> Share

  169. FRANCOLINI G, Banini M, Di Cataldo V, Detti B, et al
    PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
    Prostate. 2023;83:1201-1206.
    >> Share

    August 2023
  170. TRIPATHI N, Thomas VM, Sayegh N, Gebrael G, et al
    Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer.
    Prostate. 2023 Aug 29. doi: 10.1002/pros.24618.
    >> Share

  171. MATULEVICIUS A, Zukauskaite K, Gineikaite R, Dasevicius D, et al
    Combination of DNA methylation biomarkers with multiparametric magnetic resonance and ultrasound imaging fusion biopsy to detect the local spread of prostate cancer.
    Prostate. 2023 Aug 23. doi: 10.1002/pros.24615.
    >> Share

  172. WU S, Ma X, Liang Z, Jiang Y, et al
    Development and validation of a nomogram for predicting osteoporosis in prostate cancer patients: A cross-sectional study from China.
    Prostate. 2023 Aug 17. doi: 10.1002/pros.24612.
    >> Share

  173. CHIANG YC, Leu WJ, Chen YC, Ye PC, et al
    Mechanistic study of dual-function inhibitors targeting topoisomerase II and Rad51-mediated DNA repair pathway against castration-resistant prostate cancer.
    Prostate. 2023 Aug 15. doi: 10.1002/pros.24613.
    >> Share

  174. MATTLET A, Limani K, Alexandre P, Hawaux E, et al
    External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound.
    Prostate. 2023 Aug 13. doi: 10.1002/pros.24614.
    >> Share

  175. FU B, Wang L, Jia T, Wei Z, et al
    Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer.
    Prostate. 2023 Aug 11. doi: 10.1002/pros.24603.
    >> Share

  176. ISAACS JT, Dalrymple SL, Antony L, Marc Rosen D, et al
    Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1alpha, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
    Prostate. 2023 Aug 9. doi: 10.1002/pros.24606.
    >> Share

  177. O'CONNOR-CORDOVA MA, Macias AGO, Sancen-Herrera JP, Altamirano-Lamarque F, et al
    Surgical and functional outcomes of Retzius-sparing robotic-assisted radical prostatectomy versus conventional robotic-assisted radical prostatectomy in patients with biopsy-confirmed prostate cancer. Are outcomes worth it? Systematic review and meta-
    Prostate. 2023 Aug 9. doi: 10.1002/pros.24604.
    >> Share

  178. SLUSARCZYK A, Baboudjian M, Zapala P, Yanagisawa T, et al
    Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
    Prostate. 2023 Aug 7. doi: 10.1002/pros.24609.
    >> Share

  179. ZHANG Y, Liao Y, Luo M, Ye Y, et al
    IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
    Prostate. 2023 Aug 7. doi: 10.1002/pros.24607.
    >> Share

  180. CAO H, Xu W, Xu Y, Rong X, et al
    Value of synthetic MRI quantitative parameters in preprocedural evaluation for TRUS/MRI fusion-guided biopsy of the prostate.
    Prostate. 2023;83:1089-1098.
    >> Share

  181. MANNAS MP, Jones D, Deng FM, Hoskoppal D, et al
    Stimulated Raman histology, a novel method to allow for rapid pathologic examination of unprocessed, fresh prostate biopsies.
    Prostate. 2023;83:1060-1067.
    >> Share

  182. JIMENEZ-GARCIA IE, Sabater S, Martinez-Gutierrez R, Sanchez-Galiano P, et al
    LDR brachytherapy offers superior tumor control to single-fraction HDR prostate brachytherapy: A prospective study.
    Prostate. 2023;83:1068-1075.
    >> Share

  183. PEREIRA V, Oyekunle T, Janes J, Amling CJ, et al
    Time from biopsy to radical prostatectomy by race in an equal-access healthcare system: Results from the SEARCH cohort.
    Prostate. 2023;83:1011-1019.
    >> Share

  184. GOSSLER C, Pfander F, Haas M, Mayr R, et al
    Risk factors for bladder neck contracture after transurethral resection of the prostate.
    Prostate. 2023;83:1020-1027.
    >> Share

    July 2023
  185. YAN R, Dai W, Mao Y, Yu G, et al
    Melittin inhibits tumor cell migration and enhances cisplatin sensitivity by suppressing IL-17 signaling pathway gene LCN2 in castration-resistant prostate cancer.
    Prostate. 2023 Jul 30. doi: 10.1002/pros.24605.
    >> Share

  186. ZHANG Z, Wang X, Kim M, He D, et al
    Downregulation of EZH2 inhibits epithelial-mesenchymal transition in enzalutamide-resistant prostate cancer.
    Prostate. 2023 Jul 20. doi: 10.1002/pros.24602.
    >> Share

  187. DEIVASIGAMANI S, Orabi H, El-Shafei A, Adams ES, et al
    Intermediate-term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score-matched analysis.
    Prostate. 2023 Jul 19. doi: 10.1002/pros.24600.
    >> Share

  188. WENZEL M, Garcia CC, Hoeh B, Jorias C, et al
    Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
    Prostate. 2023 Jul 18. doi: 10.1002/pros.24599.
    >> Share

  189. ELSHAFEI A, Al-Toubat M, Feibus AH, Koul K, et al
    Genetic mutations in smoking-associated prostate cancer.
    Prostate. 2023 Jul 16. doi: 10.1002/pros.24554.
    >> Share

  190. STANGL-KREMSER J, Sun M, Ho B, Thomas J, et al
    Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
    Prostate. 2023 Jul 9. doi: 10.1002/pros.24597.
    >> Share

  191. HERNANDEZ-PEREZ JG, Lopez DS, Rodriguez-Valentin R, Vazquez-Salas RA, et al
    Late puberty onset and lack of acne during adolescence reduce high-grade prostate cancer at adulthood.
    Prostate. 2023 Jul 6. doi: 10.1002/pros.24596.
    >> Share

  192. GOMEZ GOMEZ E, Cano Castineira R, Burgos J, Rodriguez Antolin A, et al
    ProsTAV, a novel blood-based test for biopsy decision management in significant prostate cancer.
    Prostate. 2023 Jul 6. doi: 10.1002/pros.24594.
    >> Share

  193. GRUEN A, Tegel K, Kluge A, Budach V, et al
    PSMA PET-based stereotactic body radiotherapy for locally recurrent prostate cancer after definitive first-line therapy.
    Prostate. 2023 Jul 2. doi: 10.1002/pros.24592.
    >> Share

  194. PARKER R, Bell A, Chang K, Greenberg S, et al
    PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
    Prostate. 2023;83:922-928.
    >> Share

    June 2023
  195. ARAFA AT, Blader LR, Ramakrishna K, Engle J, et al
    Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
    Prostate. 2023 Jun 19. doi: 10.1002/pros.24589.
    >> Share

  196. HARA T, Terakawa T, Okamura Y, Bando Y, et al
    Real-world analysis of metastatic prostate cancer demonstrates increased frequency of PSA-imaging discordance with visceral metastases and upfront ARAT/docetaxel therapy.
    Prostate. 2023 Jun 14. doi: 10.1002/pros.24588.
    >> Share

  197. ARENAS-GALLO C, Rhodes S, Garcia JA, Weinstein I, et al
    Prostate cancer genetic alterations in Hispanic men.
    Prostate. 2023 Jun 10. doi: 10.1002/pros.24586.
    >> Share

  198. MODONUTTI D, Majdalany SE, Butaney M, Davis MJ, et al
    Conditional survival does not improve over time in metastatic castration-resistant prostate cancer patients undergoing docetaxel.
    Prostate. 2023 Jun 8. doi: 10.1002/pros.24583.
    >> Share

  199. TRINH JQ, Lele SM, Teply BA
    A case of metastatic adenoid cystic (basal cell) carcinoma of the prostate: Systemic therapy for a rare disease.
    Prostate. 2023;83:814-819.
    >> Share

  200. ZHAO J, Epstein J
    Significance of extraprostatic extension by Grade Groups 1-3 prostatic carcinoma on needle biopsy.
    Prostate. 2023;83:809-813.
    >> Share

  201. ALLALI S, Loap P, Bibault JE, Krepps S, et al
    Salvage stereotactic reirradiation for intraprostatic cancer recurrence: A large retrospective study.
    Prostate. 2023;83:743-750.
    >> Share

  202. KADONO Y, Nohara T, Kawaguchi S, Kadomoto S, et al
    Postoperative functional and cancer control evaluation of conventional and Retzius-sparing robot-assisted radical prostatectomy: Comparison of selected cases by propensity score matching.
    Prostate. 2023;83:773-780.
    >> Share

  203. BOSLAND MC, Vega K, Horton L, Schlicht MJ, et al
    Hormonal and genotoxic estrogen-androgen carcinogenesis in the NBL rat prostate: A role for aromatase.
    Prostate. 2023;83:823-830.
    >> Share

    May 2023
  204. ROBINSON T, Escara-Wilke J, Dai J, Zimmermann J, et al
    A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
    Prostate. 2023 May 27. doi: 10.1002/pros.24584.
    >> Share

  205. SENA LA, Wang H, Denmeade SR
    First, do no harm: The unclear benefit of lifelong castration for patients with metastatic prostate cancer.
    Prostate. 2023 May 27. doi: 10.1002/pros.24582.
    >> Share

  206. ZEIGLER-JOHNSON C, McDonald AC, Pinheiro P, Lynch S, et al
    Trends in prostate cancer incidence among Black men in the Caribbean and the United States.
    Prostate. 2023 May 27. doi: 10.1002/pros.24580.
    >> Share

  207. MAEDA K, Shigemura K, Hayashi F, Kan Y, et al
    Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model.
    Prostate. 2023 May 23. doi: 10.1002/pros.24581.
    >> Share

  208. WERNER RA, Lutje S, Habacha B, Bundschuh L, et al
    Test-retest repeatability of organ uptake on PSMA-targeted (18) F-DCFPyL PET/CT in patients with prostate cancer.
    Prostate. 2023 May 21. doi: 10.1002/pros.24577.
    >> Share

  209. HAZELTON J, Kim S, Boerner JL, Podgorski I, et al
    (18) F-sodium fluoride positron emission tomography quantitation of bone metastases in African American and non-African American men with metastatic prostate cancer.
    Prostate. 2023 May 21. doi: 10.1002/pros.24578.
    >> Share

  210. LUO D, Wang X, Ramamurthy G, Walker E, et al
    Evaluation of a photodynamic therapy agent using a canine prostate cancer model.
    Prostate. 2023 May 21. doi: 10.1002/pros.24560.
    >> Share

  211. KHAN S, Chang SH, Seyerle AA, Wang M, et al
    Post-diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer.
    Prostate. 2023 May 16. doi: 10.1002/pros.24557.
    >> Share

  212. SHEN K, Yu M, Ji Y, Zhou X, et al
    (18) F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.
    Prostate. 2023 May 15. doi: 10.1002/pros.24559.
    >> Share

  213. ONAL C, Erbay G, Guler OC, Yavas C, et al
    Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patients.
    Prostate. 2023 May 12. doi: 10.1002/pros.24558.
    >> Share

  214. DU X, Dong Y, Liu J, Su Y, et al
    Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
    Prostate. 2023 May 10. doi: 10.1002/pros.24553.
    >> Share

  215. MO G, Reder NP, Schweizer MT
    Evaluation of initial prostate cancer biopsies utilizing 3D open-top light-sheet microscopy for detection of early disease.
    Prostate. 2023 May 10. doi: 10.1002/pros.24555.
    >> Share

  216. MARRONE MT, Prizment AE, Couper D, Butler KR, et al
    Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.
    Prostate. 2023 May 8. doi: 10.1002/pros.24546.
    >> Share

  217. FREGO N, Labban M, Stone BV, Koelker M, et al
    Effect of type of definitive treatment on race-based differences in prostate cancer-specific survival.
    Prostate. 2023 May 7. doi: 10.1002/pros.24552.
    >> Share

  218. HENDERSON RH, Bryant C, Nichols RC Jr, Mendenhall WM, et al
    Local salvage of radiorecurrent prostate cancer.
    Prostate. 2023 May 7. doi: 10.1002/pros.24551.
    >> Share

  219. DERLIN T, Riethdorf S, Schumacher U, Lafos M, et al
    PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy.
    Prostate. 2023 May 5. doi: 10.1002/pros.24549.
    >> Share

  220. SEMSARIAN CR, Ma T, Nickel B, Barratt A, et al
    Low-risk prostate lesions: An evidence review to inform discussion on losing the "cancer" label.
    Prostate. 2023;83:498-515.
    >> Share

  221. WERNER RA, Habacha B, Lutje S, Bundschuh L, et al
    Lack of repeatability of radiomic features derived from PET scans: Results from a (18) F-DCFPyL test-retest cohort.
    Prostate. 2023;83:547-554.
    >> Share

  222. NAKAI Y, Tanaka N, Asakawa I, Hori S, et al
    Quality of life in patients who underwent robot-assisted radical prostatectomy compared with those who underwent low-dose-rate brachytherapy.
    Prostate. 2023;83:701-712.
    >> Share

  223. SZE C, Singh Z, Punyala A, Satya P, et al
    Feasibility and preliminary clinical tolerability of low-field MRI-guided prostate biopsy.
    Prostate. 2023;83:656-662.
    >> Share

    April 2023
  224. LIANG H, Zhang L, Liu Z, Hoden B, et al
    Upregulation of TLR5 indicates a favorable prognosis in prostate cancer.
    Prostate. 2023 Apr 28. doi: 10.1002/pros.24545.
    >> Share

  225. JANG A, Lanka SM, Huang M, Casado CV, et al
    Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
    Prostate. 2023 Apr 27. doi: 10.1002/pros.24544.
    >> Share

  226. VARDAKI I, Ozcan SS, Fonseca P, Lin SH, et al
    Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer.
    Prostate. 2023 Apr 19. doi: 10.1002/pros.24536.
    >> Share

  227. ROY S, Wallis CJD, Morgan SC, Kishan AU, et al
    Implications of metastatic stage at presentation in docetaxel naive metastatic castrate resistant prostate cancer.
    Prostate. 2023 Apr 18. doi: 10.1002/pros.24512.
    >> Share

  228. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
    Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
    Prostate. 2023 Apr 18. doi: 10.1002/pros.24541.
    >> Share

  229. NATANI S, Ramakrishna M, Nallavolu T, Ummanni R, et al
    MicroRNA-147b induces neuroendocrine differentiation of prostate cancer cells by targeting ribosomal protein RPS15A.
    Prostate. 2023 Apr 17. doi: 10.1002/pros.24535.
    >> Share

  230. DITE GS, Spaeth E, Murphy NM, Allman R, et al
    Development and validation of a simple prostate cancer risk prediction model based on age, family history, and polygenic risk.
    Prostate. 2023 Apr 16. doi: 10.1002/pros.24537.
    >> Share

  231. THEDERAN I, Pott A, Krueger A, Chandrasekar T, et al
    Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program.
    Prostate. 2023 Apr 13. doi: 10.1002/pros.24534.
    >> Share

  232. DUNCAN I, Ingold N, Martinez-Marroquin E, Paterson C, et al
    An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Prostate. 2023 Apr 12. doi: 10.1002/pros.24538.
    >> Share

  233. LU JG, Lo ET, Williams C, Ma B, et al
    Expression of high molecular weight cytokeratin-A novel feature of aggressive and innate hormone-refractory prostatic adenocarcinoma.
    Prostate. 2023;83:462-469.
    >> Share

    March 2023
  234. ARAFA AT, Jain A, Skrobanek P, Humphrey B, et al
    Impact of piflufolastat F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states: A retrospective review.
    Prostate. 2023 Mar 31. doi: 10.1002/pros.24527.
    >> Share

  235. ADORNO FEBLES VR, Hao Y, Ahsan A, Wu J, et al
    Single-cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile.
    Prostate. 2023 Mar 29. doi: 10.1002/pros.24524.
    >> Share

  236. SAEMUNDSSON A, Xu LD, Meisgen F, Cao R, et al
    Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients.
    Prostate. 2023 Mar 29. doi: 10.1002/pros.24530.
    >> Share

  237. MAFFEI D, Fasulo V, Avolio PP, Saitta C, et al
    Diagnostic performance of Micro-Ultrasound at MRI-guided confirmatory biopsy in patients under active surveillance for low-risk prostate cancer.
    Prostate. 2023 Mar 24. doi: 10.1002/pros.24532.
    >> Share

  238. STANGL-KREMSER J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, et al
    Response to RL-225Ac in prostate cancer: effect of prior treatment with RL-177Lu: a systematic review of the literature.
    Prostate. 2023 Mar 24. doi: 10.1002/pros.24531.
    >> Share

  239. OERTHER B, Engel H, Nedelcu A, Schlett CL, et al
    Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: performance of a fully automated AI-algorithm for lesion detection and classification.
    Prostate. 2023 Mar 23. doi: 10.1002/pros.24528.
    >> Share

  240. CAPUTO SA, Hawkins M, Jaeger EB, Fleming W, et al
    Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer.
    Prostate. 2023 Mar 23. doi: 10.1002/pros.24529.
    >> Share

  241. HASAN S, Lazarev S, Garg M, Gozland R, et al
    Proton therapy for high-risk prostate cancer: Results from the Proton Collaborative Group PCG 001-09 prospective registry trial.
    Prostate. 2023 Mar 22. doi: 10.1002/pros.24525.
    >> Share

  242. WONG CHM, Xu N, Lim J, Feng KK, et al
    Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study.
    Prostate. 2023 Mar 20. doi: 10.1002/pros.24519.
    >> Share

  243. ROBECK P, Xu L, Ahmed D, Dragomir A, et al
    P-score in preoperative biopsies accurately predicts P-score in final pathology at radical prostatectomy in patients with localized prostate cancer.
    Prostate. 2023 Mar 20. doi: 10.1002/pros.24523.
    >> Share

  244. LEWIS AR, Costello BA, Quevedo F, Pagliaro LC, et al
    Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.
    Prostate. 2023 Mar 16. doi: 10.1002/pros.24498.
    >> Share

  245. TELLI T, Tuncel M, Karabulut E, Aksoy S, et al
    Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with (177) Lu-PSMA-617. A single-center prospective observational study.
    Prostate. 2023 Mar 15. doi: 10.1002/pros.24518.
    >> Share

  246. CHIERIGO F, Flammia RS, Sorce G, Hoeh B, et al
    The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy.
    Prostate. 2023 Mar 15. doi: 10.1002/pros.24505.
    >> Share

  247. TAN YG, Law YM, Ngo NT, Khor LY, et al
    Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24517.
    >> Share

  248. CHAMORRO CASTILLO L, Garcia Morales L, Ruiz Lopez D, Salguero Segura J, et al
    The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24515.
    >> Share

  249. MIYAZAWA Y, Nakamura T, Takezawa Y, Shimizu N, et al
    A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS.
    Prostate. 2023 Mar 9. doi: 10.1002/pros.24514.
    >> Share

  250. CONOVER MM, Weaver J, Fan B, Leitz G, et al
    Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data.
    Prostate. 2023 Mar 6. doi: 10.1002/pros.24510.
    >> Share

  251. STINSON J, McCall C, Dobbs RW, Mistry N, et al
    Vitamin D and genetic ancestry are associated with apoptosis rates in benign and malignant prostatic epithelium.
    Prostate. 2023;83:352-363.
    >> Share

  252. REN J, Melamed J, Taneja SS, Wysock JS, et al
    Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Prostate. 2023;83:323-330.
    >> Share

    February 2023
  253. BECK J, Rouleau M, Lemire F, Neveu B, et al
    Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
    Prostate. 2023 Feb 27. doi: 10.1002/pros.24501.
    >> Share

  254. ZHUANG Q, Huang S, Li Z
    Prospective role of 3betaHSD1 in prostate cancer precision medicine.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24504.
    >> Share

  255. OYENUGA M, Halabi S, Oyenuga A, McSweeney S, et al
    Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24503.
    >> Share

  256. LEE J, Wickes BL, Fu J, Brockman NE, et al
    Prevalence of genotoxic bacteria in men undergoing biopsy for prostate cancer.
    Prostate. 2023 Feb 26. doi: 10.1002/pros.24500.
    >> Share

  257. TIRUYE T, O'Callaghan M, Ettridge K, Jay A, et al
    Factors impacting on sexual function among men on active surveillance for prostate cancer.
    Prostate. 2023 Feb 24. doi: 10.1002/pros.24502.
    >> Share

  258. ADAMS MN, Croft LV, Urquhart A, Saleem MAM, et al
    hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen-induced transcriptional response in prostate cancer.
    Prostate. 2023 Feb 22. doi: 10.1002/pros.24496.
    >> Share

  259. CHEN LC, Huang SP, Shih CT, Li CY, et al
    ATP8B1: A prognostic prostate cancer biomarker identified via genetic analysis.
    Prostate. 2023 Feb 15. doi: 10.1002/pros.24495.
    >> Share

  260. GRAHAM LS, Haffner MC, Sayar E, Gawne A, et al
    Clinical, pathologic, and molecular features of amphicrine prostate cancer.
    Prostate. 2023 Feb 13. doi: 10.1002/pros.24497.
    >> Share

  261. TAKESHITA N, Sakamoto S, Yamada Y, Sazuka T, et al
    Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.
    Prostate. 2023 Feb 10. doi: 10.1002/pros.24492.
    >> Share

  262. KARTHIKEYAN SK, Xu N, Ferguson Rd JE, Rais-Bahrami S, et al
    Identification of androgen response-related lncRNAs in prostate cancer.
    Prostate. 2023 Feb 9. doi: 10.1002/pros.24494.
    >> Share

    January 2023
  263. BRAY G, Bahadori A, Rama D
    Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24491.
    >> Share

  264. RAM P, Mandal S, K Das M, Nayak P, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2023 Jan 30. doi: 10.1002/pros.24489.
    >> Share

  265. DIAMAND R, Peltier A, Roche JB, Lievore E, et al
    Risk stratification for early biochemical recurrence of prostate cancer in the era of multiparametric magnetic resonance imagining-targeted biopsy.
    Prostate. 2023 Jan 27. doi: 10.1002/pros.24490.
    >> Share

  266. YANAGISAWA T, Hata K, Narita S, Hatakeyama S, et al
    Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Prostate. 2023 Jan 20. doi: 10.1002/pros.24488.
    >> Share

  267. RAM P, Nayak P, Mandal S, Das MK, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24487.
    >> Share

  268. DAVIDSSON S, Messing Eriksson A, Udumyan R, Swanholm P, et al
    Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
    Prostate. 2023 Jan 19. doi: 10.1002/pros.24485.
    >> Share

  269. STANGL A, Wilner C, Li P, Maahs L, et al
    Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Prostate. 2023 Jan 5. doi: 10.1002/pros.24481.
    >> Share

  270. MAVURA Y, Song H, Xie J, Tamayo P, et al
    Transcriptomic profiling and genomic rearrangement landscape of Nigerian prostate cancer.
    Prostate. 2023 Jan 4. doi: 10.1002/pros.24471.
    >> Share

  271. BHAT TA, Dheeraj A, Nambiar DK, Singh SP, et al
    Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
    Prostate. 2023 Jan 3. doi: 10.1002/pros.24482.
    >> Share

  272. AGUIAR JA, Li EV, Siddiqui MR, Soliman MA, et al
    Utilization of genetic testing in men with advanced prostate cancer.
    Prostate. 2023 Jan 2. doi: 10.1002/pros.24480.
    >> Share

  273. BRODOWSKY EC, Sood A, Butaney M, Majdalany SE, et al
    Time to second biochemical recurrence as a prognostic indicator in postprostatectomy patients who undergo salvage radiation therapy: An RTOG 9601 based post hoc analysis.
    Prostate. 2023;83:64-70.
    >> Share

    December 2022
  274. CHANG T, Lian Z, Ma S, Liang Z, et al
    Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    Prostate. 2022 Dec 28. doi: 10.1002/pros.24479.
    >> Share

  275. WEI J, Beebe-Dimmer J, Shi Z, Sample C, et al
    Association of rare, recurrent nonsynonymous variants in the germline of prostate cancer patients of African ancestry.
    Prostate. 2022 Dec 25. doi: 10.1002/pros.24477.
    >> Share

  276. RAJWA P, Pfister D, Rieger C, Heidenreich J, et al
    Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer.
    Prostate. 2022 Dec 23. doi: 10.1002/pros.24470.
    >> Share

  277. FERNANDEZ-PEREZ MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, et al
    A correlative biomarker study and integrative prognostic model in chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide.
    Prostate. 2022 Dec 23:e24469. doi: 10.1002/pros.24469.
    >> Share

  278. UNTERBERGER CJ, McIlwain SJ, Tsourkas PK, Maklakova VI, et al
    Conditional gene regulation models demonstrate a pro-proliferative role for growth hormone receptor in prostate cancer.
    Prostate. 2022 Dec 22. doi: 10.1002/pros.24474.
    >> Share

  279. ROSSETTO I, Santos F, Kido L, Lamas C, et al
    Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation.
    Prostate. 2022 Dec 22. doi: 10.1002/pros.24473.
    >> Share

  280. YANG J, Tang Y, Zhou C, Zhou M, et al
    The use of (68) Ga-PSMA PET/CT to stratify patients with PI-RADS 3 lesions according to clinically significant prostate cancer risk.
    Prostate. 2022 Dec 21. doi: 10.1002/pros.24475.
    >> Share

  281. XU Y, Xu M, Li X, Weng X, et al
    SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression.
    Prostate. 2022 Dec 21. doi: 10.1002/pros.24476.
    >> Share

  282. JURACEK J, Madrzyk M, Stanik M, Ruckova M, et al
    A tissue miRNA expression pattern is associated with disease aggressiveness of localized prostate cancer.
    Prostate. 2022 Dec 8. doi: 10.1002/pros.24466.
    >> Share

  283. SASAKI T, Yoshikawa Y, Kageyama T, Sugino Y, et al
    Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Prostate. 2022 Dec 7. doi: 10.1002/pros.24468.
    >> Share

  284. KAZAN O, Gunduz N, Kir G, Iplikci A, et al
    The cribriform morphology impairs Gleason 7 prostate cancer lesion detection on multiparametric magnetic resonance imaging.
    Prostate. 2022 Dec 7. doi: 10.1002/pros.24465.
    >> Share

  285. AMARO GM, da Silva ADT, Tamarindo GH, Lamas CA, et al
    Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Prostate. 2022;82:1491-1504.
    >> Share

  286. DENMEADE S, Lim SJ, Isaaccson Velho P, Wang H, et al
    PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Prostate. 2022;82:1529-1536.
    >> Share

    November 2022
  287. MIYAHIRA AK, Hawley JE, Adelaiye-Ogala R, Calais J, et al
    Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2022 Nov 28. doi: 10.1002/pros.24461.
    >> Share

  288. NAITO Y, Kato M, Kawanishi H, Yamamoto A, et al
    Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
    Prostate. 2022 Nov 24. doi: 10.1002/pros.24462.
    >> Share

  289. SU CT, Nizialek E, Berchuck JE, Vlachostergios PJ, et al
    Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Prostate. 2022 Nov 16. doi: 10.1002/pros.24454.
    >> Share

  290. ALASKAR A, Abdulraqeb Ali A, Hassan S, Shinwari Z, et al
    Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
    Prostate. 2022 Nov 14. doi: 10.1002/pros.24455.
    >> Share

  291. TRABZONLU L, Pienta KJ, Trock BJ, De Marzo AM, et al
    Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
    Prostate. 2022 Nov 13. doi: 10.1002/pros.24459.
    >> Share

  292. PANUNZIO A, Sorce G, Hoeh B, Hohenhorst L, et al
    Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
    Prostate. 2022 Nov 6. doi: 10.1002/pros.24458.
    >> Share

  293. NYGARD LH, Talala K, Taari K, Tammela TLJ, et al
    Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia.
    Prostate. 2022 Nov 3. doi: 10.1002/pros.24456.
    >> Share

  294. CHAN JSK, Tang P, Hui JMH, Lee YHA, et al
    Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis.
    Prostate. 2022;82:1477-1480.
    >> Share

  295. BROWN NE, Jones A, Hunt BG, Waltz SE, et al
    Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Prostate. 2022;82:1422-1437.
    >> Share

    October 2022
  296. LEE EE, Singh T, Hu C, Han M, et al
    The impact of salvage radiotherapy initiation at PSA
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24452.
    >> Share

  297. OISHI T, Hatakeyama S, Tabata R, Fujimori D, et al
    Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24453.
    >> Share

  298. NIU S, Liu Y, Ding X, Xu Y, et al
    (18) F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis.
    Prostate. 2022 Oct 25. doi: 10.1002/pros.24446.
    >> Share

  299. ODERDA M, Albisinni S, Benamran D, Calleris G, et al
    Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24449.
    >> Share

  300. SATAPATHY S, Das CK, Aggarwal P, Sood A, et al
    Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24450.
    >> Share

  301. CHENG S, Yu X
    CTPC, a combined transcriptome data set of human prostate cancer cell lines.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24448.
    >> Share

  302. HARPER JB, Greenberg SE, Hunt TC, Cooney KA, et al
    Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24447.
    >> Share

  303. OU W, Lei J, Li M, Zhang X, et al
    Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24442.
    >> Share

  304. HARTRAMPF PE, Weinzierl FX, Seitz AK, Kubler H, et al
    Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
    Prostate. 2022;82:1406-1412.
    >> Share

  305. VERMA S, Kushwaha PP, Shankar E, Ponsky LE, et al
    Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
    Prostate. 2022;82:1389-1399.
    >> Share

  306. WONG WW, Hillman DW, Daniels TB, Vargas CE, et al
    A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.
    Prostate. 2022;82:1338-1345.
    >> Share

    September 2022
  307. LEE YHA, Hui JMH, Chan JSK, Liu K, et al
    Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
    Prostate. 2022 Sep 30. doi: 10.1002/pros.24443.
    >> Share

  308. MUSTAFFA A, Emara S
    Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24444.
    >> Share

  309. URABE F, Miki K, Kimura T, Sasaki H, et al
    Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24445.
    >> Share

  310. WANG S, Zhang C, Xu Z, Chen MH, et al
    Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
    Prostate. 2022 Sep 26. doi: 10.1002/pros.24441.
    >> Share

  311. ALAMIRI J, Britton CJ, Ahmed ME, Andrews JR, et al
    Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Prostate. 2022 Sep 11. doi: 10.1002/pros.24413.
    >> Share

  312. SCHMID FA, Lieger L, Saba K, Sigg S, et al
    Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24435.
    >> Share

  313. LIN R, Yang Y, Wu E, Zhou M, et al
    SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24437.
    >> Share

  314. SCHOBER JP, Stensland KD, Moinzadeh A, Canes D, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24433.
    >> Share

  315. KC M, Oral E, Rung AL, Trapido E, et al
    Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24434.
    >> Share

    August 2022
  316. SEMIZ HS, Kucuk U, Kisa E, Keskinkilic M, et al
    CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
    Prostate. 2022 Aug 28. doi: 10.1002/pros.24432.
    >> Share

  317. RUAN X, Huang D, Huang J, Xu D, et al
    Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24431.
    >> Share

  318. KARELIA DN, Kim S, Plano D, Sharma AK, et al
    Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24430.
    >> Share

  319. DYMANUS K, Howard LE, Oyekunle T, De Hoedt AM, et al
    Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24429.
    >> Share

  320. FILON MJ, Gillette AA, Yang B, Khemees TA, et al
    Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24428.
    >> Share

  321. MAYNARD JP, Godwin TN, Lu J, Vidal I, et al
    Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24424.
    >> Share

  322. TAKAMORI H, Urabe F, Matsuzaki J, Kimura S, et al
    Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24427.
    >> Share

  323. TERRACCIANO D, La Civita E, Athanasiou A, Liotti A, et al
    New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24422.
    >> Share

  324. WANG S, Ryan Russell J, Drescher M, Park A, et al
    Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
    >> Share

  325. LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
    Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
    >> Share

  326. KWAN EM, Wyatt AW
    Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
    Prostate. 2022;82 Suppl 1:S25-S36.
    >> Share

  327. SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
    Genomic biomarkers to guide precision radiotherapy in prostate cancer.
    Prostate. 2022;82 Suppl 1:S73-S85.
    >> Share

  328. KHAN HM, Cheng HH
    Germline genetics of prostate cancer.
    Prostate. 2022;82 Suppl 1:S3-S12.
    >> Share

  329. CRESTA MORGADO P, Mateo J
    Clinical implications of homologous recombination repair mutations in prostate cancer.
    Prostate. 2022;82 Suppl 1:S45-S59.
    >> Share

  330. COTTER K, Rubin MA
    The evolving landscape of prostate cancer somatic mutations.
    Prostate. 2022;82 Suppl 1:S13-S24.
    >> Share

  331. ANTONARAKIS ES
    Genetics and genomics of prostate cancer and therapeutic implications.
    Prostate. 2022;82 Suppl 1:S1-S2.
    >> Share

  332. MIZUNO K, Beltran H
    Future directions for precision oncology in prostate cancer.
    Prostate. 2022;82 Suppl 1:S86-S96.
    >> Share

  333. CHOUDHURY AD
    PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Prostate. 2022;82 Suppl 1:S60-S72.
    >> Share

  334. LI G, Xia YF, Huang YX, Okat D, et al
    Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
    >> Share

  335. UCAR T, Gunduz N, Demirci E, Culpan M, et al
    Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
    >> Share

    July 2022
  336. YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
    Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
    Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
    >> Share

  337. KHAN S, Vohra S, Farnan L, Elmore SNC, et al
    Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
    Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
    >> Share

  338. WANG Y, Tang Y, Gao X, Gan Y, et al
    Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
    Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
    >> Share

  339. MIYAHIRA AK, Soule HR
    The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
    >> Share

  340. MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
    A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
    >> Share

  341. RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
    Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
    >> Share

    June 2022
  342. YANAGISAWA T, Kimura T, Hata K, Narita S, et al
    Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
    >> Share

  343. CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
    Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
    >> Share

  344. BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
    Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
    >> Share

  345. MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
    Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
    >> Share

  346. YANG T, Liu Y, Chen S, Tian J, et al
    Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
    >> Share

  347. HEARD JR, Huang AJ, Werle L, Adler K, et al
    Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
    >> Share

  348. STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
    The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
    >> Share

  349. LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
    >> Share

  350. SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
    Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
    >> Share

  351. CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
    Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
    >> Share

  352. ABDI B, Basset N, Perrot E, Benderra MA, et al
    DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
    >> Share

  353. MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
    Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
    Prostate. 2022;82:933-941.
    >> Share

  354. FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
    Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
    Prostate. 2022;82:904-910.
    >> Share

  355. HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
    Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
    Prostate. 2022;82:894-903.
    >> Share

  356. RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
    Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
    Prostate. 2022;82:970-983.
    >> Share

    May 2022
  357. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    >> Share

  358. PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
    Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
    Prostate. 2022 May 10. doi: 10.1002/pros.24368.
    >> Share

  359. HE Y, Shen Q, Fu W, Wang H, et al
    Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    Prostate. 2022 May 10. doi: 10.1002/pros.24365.
    >> Share

  360. MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
    Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
    Prostate. 2022 May 10. doi: 10.1002/pros.24369.
    >> Share

  361. SAKELLAKIS M
    Orphan receptors in prostate cancer.
    Prostate. 2022 May 10. doi: 10.1002/pros.24370.
    >> Share

  362. KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
    Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
    Prostate. 2022 May 10. doi: 10.1002/pros.24363.
    >> Share

  363. DENMEADE S, Antonarakis ES, Markowski MC
    Bipolar androgen therapy (BAT): A patient's guide.
    Prostate. 2022;82:753-762.
    >> Share

  364. VITEK RA, Huang W, Geiger PG, Heninger E, et al
    Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
    Prostate. 2022;82:836-849.
    >> Share

  365. LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
    Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
    Prostate. 2022;82:804-808.
    >> Share

    April 2022
  366. BOSLAND MC, Horton L, Condon MS
    Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
    Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
    >> Share

  367. WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
    Current and projected number of years of life lost due to prostate cancer: A global study.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
    >> Share

  368. WANG M, Qi J, George AK, Semerjian A, et al
    The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
    >> Share

  369. HU Q, Hong X, Xu L, Jia R, et al
    A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
    >> Share

  370. YUEN KC, Tran B, Anton A, Hamidi H, et al
    Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
    Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
    >> Share

  371. PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
    Prostate cancer awareness among transgender women after gender-affirming surgery.
    Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
    >> Share

  372. MORI JO, Shafran JS, Stojanova M, Katz MH, et al
    Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
    >> Share

  373. FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
    Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
    >> Share

  374. LV X, Li Y, Li R, Guan X, et al
    Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
    >> Share

  375. SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
    Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
    >> Share

  376. YAMAGUCHI M, Murata T, Ramos JW
    Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
    >> Share

  377. ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
    Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Prostate. 2022;82:556-565.
    >> Share

  378. CHEN Z, Wu J, Sun K, He Y, et al
    Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
    Prostate. 2022;82:566-575.
    >> Share

  379. LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
    Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Prostate. 2022;82:576-583.
    >> Share

  380. WEI X, Roudier MP, Kwon OJ, Lee JD, et al
    Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
    Prostate. 2022;82:517-530.
    >> Share

    March 2022
  381. GRAHAM LS, Schweizer MT
    Mismatch repair deficiency and clinical implications in prostate cancer.
    Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
    >> Share

  382. PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
    Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
    Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
    >> Share

  383. SINGH CK, Denu RA, Nihal M, Shabbir M, et al
    PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
    Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
    >> Share

  384. MAO F, Kong Y, Liu J, Rao X, et al
    Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
    Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
    >> Share

  385. LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
    Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
    Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
    >> Share

  386. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
    >> Share

  387. ZHANG T, Kephart J, Bronson E, Anand M, et al
    Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
    >> Share

  388. ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
    Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
    >> Share

  389. SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
    Immune mechanisms behind prostate cancer in men of African ancestry: A review.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
    >> Share

  390. BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
    Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
    >> Share

  391. HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
    Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
    Prostate. 2022;82:405-414.
    >> Share

  392. LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
    Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:493-501.
    >> Share

  393. KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
    Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
    Prostate. 2022;82:425-432.
    >> Share

    February 2022
  394. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
    >> Share

  395. PURAYIL HT, Daaka Y
    betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
    >> Share

  396. LIU JM, Chen YT, Wu CT, Hsu WL, et al
    Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
    >> Share

  397. K C M, Oral E, Rung AL, Trapido EJ, et al
    Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
    Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
    >> Share

  398. KANEKO M, Fukuda N, Nagano H, Yamada K, et al
    Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
    Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
    >> Share

  399. IZOL V, Ok F, Aslan G, Akdogan B, et al
    Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
    >> Share

  400. OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
    Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
    >> Share

  401. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
    >> Share

  402. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
    >> Share

  403. PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
    Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
    >> Share

  404. WANG Y, Abenojar EC, Wang J, de Leon AC, et al
    Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
    >> Share

  405. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    >> Share

  406. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2022;82:401-402.
    >> Share

  407. URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
    Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
    Prostate. 2022;82:330-344.
    >> Share

  408. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
    Prostate. 2022;82:399-400.
    >> Share

  409. HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
    Don't throw the baby out with the bath water.
    Prostate. 2022;82:397-398.
    >> Share

  410. MA C, Downes M, Jain R, Ientilucci M, et al
    Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Prostate. 2022;82:345-351.
    >> Share

  411. ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
    Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
    Prostate. 2022;82:306-313.
    >> Share

  412. ARCOT R, Cher ML, Qi J, Linsell SM, et al
    Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Prostate. 2022;82:323-329.
    >> Share

  413. TAN YG, Fang AHS, Lim JKS, Khalid F, et al
    Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
    Prostate. 2022;82:298-305.
    >> Share

  414. MA H, Xu W, Ni J, Zhao N, et al
    Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Prostate. 2022;82:276-285.
    >> Share

  415. LI N, Song WJ, Gao J, Xu ZP, et al
    The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:221-226.
    >> Share

  416. AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
    Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
    Prostate. 2022;82:235-244.
    >> Share

  417. SIEDOW M, Eisner M, Yaney A, Washington I, et al
    Impact of prostate biopsy secondary pathology review on radiotherapy management.
    Prostate. 2022;82:210-215.
    >> Share

    January 2022
  418. LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
    Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
    >> Share

  419. GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
    Protein signatures to distinguish aggressive from indolent prostate cancer.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
    >> Share

  420. ZHAO R, Lv Y, Feng T, Zhang R, et al
    ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
    >> Share

  421. STOVER EH, Oh C, Keskula P, Choudhury AD, et al
    Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
    Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
    >> Share

  422. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    >> Share

  423. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    >> Share

  424. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    >> Share

  425. CAO Y, Song DY, Deville C, DeWeese TL, et al
    Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
    Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
    >> Share

  426. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    >> Share

  427. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    >> Share

  428. SEREF C, Acar O, Kilic M, Vural M, et al
    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
    Prostate. 2022;82:145-153.
    >> Share

  429. YUAN W, Liu B, Sanda M, Wei R, et al
    Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
    Prostate. 2022;82:132-144.
    >> Share

  430. WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
    Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
    Prostate. 2022;82:86-96.
    >> Share

    December 2021
  431. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    >> Share

  432. MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
    MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
    Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
    >> Share

  433. SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
    Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
    Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
    >> Share

  434. HE H, Han D, Xu F, Lyu J, et al
    How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
    >> Share

  435. URABE F, Miki K, Kimura T, Sasaki H, et al
    Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
    >> Share

  436. KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
    Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
    >> Share

  437. BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
    Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
    >> Share

  438. LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
    Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
    >> Share

  439. POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
    Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
    >> Share

  440. ZAREI A, Javid H, Sanjarian S, Senemar S, et al
    Metagenomics studies for the diagnosis and treatment of prostate cancer.
    Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
    >> Share

  441. MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
    The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
    Prostate. 2021;81:1428-1434.
    >> Share

  442. NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
    Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
    Prostate. 2021;81:1355-1364.
    >> Share

  443. YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
    Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Prostate. 2021;81:1402-1410.
    >> Share

  444. TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
    The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
    Prostate. 2021;81:1287-1293.
    >> Share

  445. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
    Prostate. 2021;81:1294-1302.
    >> Share

    November 2021
  446. NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
    Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
    >> Share

  447. VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
    Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
    >> Share

  448. PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
    Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
    >> Share

  449. PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
    Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
    >> Share

  450. NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
    Clinical and genomic features of SPOP-mutant prostate cancer.
    Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
    >> Share

  451. TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
    Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
    >> Share

  452. HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
    Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
    >> Share

  453. MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
    Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
    >> Share

    October 2021
  454. SHI Z, Lu L, Resurreccion WK, Yang W, et al
    Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
    >> Share

  455. PILLING A, Kim SH, Hwang C
    Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
    >> Share

  456. LUO LS, Jiang JF, Luan HH, Zi H, et al
    Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
    >> Share

  457. KIM S, Li L, Zhang J, Jiang C, et al
    Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
    >> Share

  458. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
    >> Share

  459. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
    >> Share

  460. IKEUCHI W, Wakita Y, Zhang G, Li C, et al
    AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
    >> Share

  461. JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
    Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
    >> Share

  462. PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
    The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
    Prostate. 2021;81:1064-1070.
    >> Share

    September 2021
  463. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    >> Share

  464. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    >> Share

  465. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    >> Share

  466. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    >> Share

  467. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    >> Share

  468. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
    >> Share

  469. JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
    Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
    >> Share

  470. LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
    Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
    >> Share

  471. AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
    The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
    >> Share

  472. WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
    PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
    >> Share

  473. LIU Y, Dong Y, Liu J, Zhang X, et al
    Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
    >> Share

  474. CHHATRE S, Malkowicz SB, Jayadevappa R
    Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
    >> Share

  475. SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
    Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
    >> Share

  476. CHO MC, Yoo S, Choo MS, Son H, et al
    Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
    >> Share

  477. MANGOSH TL, Grabowska MM, Taylor DJ
    SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
    >> Share

  478. MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
    Pathological significance and prognostic role of LATS2 in prostate cancer.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
    >> Share

  479. MIYAHIRA AK, Soule HR
    The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
    >> Share

  480. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
    >> Share

  481. EKSI M, Evren I, Akkas F, Arikan Y, et al
    Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
    Prostate. 2021;81:913-920.
    >> Share

  482. IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
    Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Prostate. 2021;81:866-873.
    >> Share

  483. MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
    Impact of median lobe on urinary function after robotic prostatectomy.
    Prostate. 2021;81:832-837.
    >> Share

  484. LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
    Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
    Prostate. 2021;81:1009-1017.
    >> Share

  485. SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
    Stromal cell interplay in prostate development, physiology, and pathological conditions.
    Prostate. 2021;81:926-937.
    >> Share

  486. WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
    Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
    Prostate. 2021;81:938-943.
    >> Share

    August 2021
  487. LEDET EM, Sartor O
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.
    >> Share

  488. DI MAIDA F, Grosso AA, Minervini A
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.
    >> Share

  489. SHAO L, Wang J, Karatas O, Ittmann M, et al
    MEX3D is an oncogenic driver in prostate cancer.
    Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
    >> Share

  490. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    >> Share

  491. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    >> Share

  492. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    >> Share

  493. HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
    Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
    >> Share

  494. WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
    The effect of primary urological cancers on survival in men with secondary prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
    >> Share

  495. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    >> Share

  496. WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
    Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
    Prostate. 2021;81:785-793.
    >> Share

  497. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
    Prostate. 2021;81:778-784.
    >> Share

  498. WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
    Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
    Prostate. 2021;81:772-777.
    >> Share

    July 2021
  499. ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
    Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
    >> Share

  500. LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
    Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
    >> Share

  501. CAO Y, Zhang W, Li Y, Fu J, et al
    Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
    >> Share

  502. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
    Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
    >> Share

  503. CHAO OS, Goodman OB Jr
    DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
    >> Share

  504. EPSTEIN JI
    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
    >> Share

  505. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    >> Share

  506. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    >> Share

  507. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    >> Share

  508. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    >> Share

  509. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    >> Share

  510. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    >> Share

  511. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    >> Share

  512. CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
    Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
    Prostate. 2021;81:694-702.
    >> Share

    June 2021
  513. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    >> Share

  514. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    >> Share

  515. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    >> Share

  516. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    >> Share

  517. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    >> Share

  518. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    >> Share

  519. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    >> Share

  520. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    >> Share

  521. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    >> Share

  522. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
    Prostate. 2021;81:443-451.
    >> Share

  523. CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
    Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
    Prostate. 2021;81:521-529.
    >> Share

  524. XIAO GQ, Ho G, Suen C, Hurth KM, et al
    Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Prostate. 2021;81:469-477.
    >> Share

    May 2021
  525. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    >> Share

  526. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    >> Share

  527. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    >> Share

  528. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    >> Share

  529. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    >> Share

  530. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    >> Share

  531. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.
    >> Share

  532. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    >> Share

  533. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    >> Share

  534. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    >> Share

  535. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    >> Share

  536. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    >> Share

  537. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    >> Share

  538. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    >> Share

  539. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    >> Share

  540. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    >> Share

  541. ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
    Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Prostate. 2021;81:390-397.
    >> Share

    April 2021
  542. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    >> Share

  543. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    >> Share

  544. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    >> Share

  545. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    >> Share

  546. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    >> Share

  547. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    >> Share

  548. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    >> Share

  549. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    >> Share

  550. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    >> Share

    March 2021
  551. SWANSON GP, Lenz L, Stone S, Cohen T, et al
    Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Prostate. 2021;81:261-267.
    >> Share

  552. TAN YG, Khalid F, Huang HH, Chen K, et al
    Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Prostate. 2021;81:242-251.
    >> Share

  553. LI Y, Ge C, Franceschi RT
    Role of Runx2 in prostate development and stem cell function.
    Prostate. 2021;81:231-241.
    >> Share

    February 2021
  554. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    >> Share

    January 2021
  555. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016